FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020930455> ?p ?o ?g. }

• W3020930455 endingPage "e1193" @default.
• W3020930455 startingPage "e1193" @default.
• W3020930455 abstract "You have accessJournal of UrologyProstate Cancer: Staging II (PD57)1 Apr 2020PD57-01 MR/US FUSION-GUIDED PROSTATE BIOPSY IMPROVES CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION FOR BIOPSY-NAIVE PATIENTS ACROSS DIVERSE PRACTICE SETTINGS Brett Watson*, MD Ji Qi, Anna Johnson, and for the Michigan Urological Surgery Improvement Collaborative Brett Watson*Brett Watson* More articles by this author , Ji QiJi Qi More articles by this author , Anna JohnsonAnna Johnson More articles by this author , and for the Michigan Urological Surgery Improvement Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000967.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Multicenter trials have compared fusion to systematic prostate biopsy in the biopsy-naive population. These reports are predominantly from large academic centers with significant expertise. However, the added value of MR targeted biopsy for biopsy-naive patients in the community setting is largely unknown. METHODS: The Michigan Urological Surgery Improvement Collaborative (MUSIC) registry maintains a prospective MR and fusion biopsy database with technical, patient, provider, and lesion level data. All patients undergoing targeted and systematic biopsy in the same setting with no prior biopsy from August 2017 - May 2019 were included. Software-based MR/US fusion was used in all cases. Primary outcomes were the proportion of patients upgraded to ≥GG2 prostate cancer (PCa) by target and the proportion upgraded to ≥GG2 PCa based on systematic biopsy. RESULTS: Of 2375 fusion biopsies in the registry, 437 patients from 22 practices met inclusion criteria. Median age and pre-diagnosis PSA for the cohort was 66 years and 6.3 ng/ml, respectively. Overall cancer detection rate was 76.4% and the rate of clinically significant prostate cancer (csPCa) detection was 51.9%. Of the 227 cases of csPCa, 16% were detected by standard biopsy only, 17% by targeted biopsy only, and 67% by both techniques. Of all patients, 39 (8.9%) were upgraded to csPCa by targeted biopsy while 36 (8.2%) were upgraded to csPCa by standard biopsy. On bivariate analysis, we did not identify significant factors predictive of upgrading to csPCa by either technique. CONCLUSIONS: In biopsy-naïve patients, targeted biopsy upgrades approximately 1 in 10 patients to ≥GG2 prostate cancer. A similar proportion of patients with negative targeted biopsies were upgraded by systematic biopsy alone. There were no clinical variables associated with upgrading to ≥GG2 PCa by either biopsy method. Our findings suggest there is value in the community setting to adding mpMRI with targeted biopsy to the initial evaluation of biopsy-naive patients. Source of Funding: MUSIC is funded by Blue Cross Blue Shield of Michigan © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1193-e1193 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Brett Watson* More articles by this author Ji Qi More articles by this author Anna Johnson More articles by this author for the Michigan Urological Surgery Improvement Collaborative More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3020930455 created "2020-05-13" @default.
• W3020930455 creator A5006621039 @default.
• W3020930455 creator A5009397033 @default.
• W3020930455 creator A5058885209 @default.
• W3020930455 date "2020-04-01" @default.
• W3020930455 modified "2023-09-27" @default.
• W3020930455 title "PD57-01 MR/US FUSION-GUIDED PROSTATE BIOPSY IMPROVES CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION FOR BIOPSY-NAIVE PATIENTS ACROSS DIVERSE PRACTICE SETTINGS" @default.
• W3020930455 doi "https://doi.org/10.1097/ju.0000000000000967.01" @default.
• W3020930455 hasPublicationYear "2020" @default.
• W3020930455 type Work @default.
• W3020930455 sameAs 3020930455 @default.
• W3020930455 citedByCount "0" @default.
• W3020930455 crossrefType "journal-article" @default.
• W3020930455 hasAuthorship W3020930455A5006621039 @default.
• W3020930455 hasAuthorship W3020930455A5009397033 @default.
• W3020930455 hasAuthorship W3020930455A5058885209 @default.
• W3020930455 hasConcept C121608353 @default.
• W3020930455 hasConcept C126322002 @default.
• W3020930455 hasConcept C126838900 @default.
• W3020930455 hasConcept C2775934546 @default.
• W3020930455 hasConcept C2776235491 @default.
• W3020930455 hasConcept C2780192828 @default.
• W3020930455 hasConcept C2781217009 @default.
• W3020930455 hasConcept C71924100 @default.
• W3020930455 hasConceptScore W3020930455C121608353 @default.
• W3020930455 hasConceptScore W3020930455C126322002 @default.
• W3020930455 hasConceptScore W3020930455C126838900 @default.
• W3020930455 hasConceptScore W3020930455C2775934546 @default.
• W3020930455 hasConceptScore W3020930455C2776235491 @default.
• W3020930455 hasConceptScore W3020930455C2780192828 @default.
• W3020930455 hasConceptScore W3020930455C2781217009 @default.
• W3020930455 hasConceptScore W3020930455C71924100 @default.
• W3020930455 hasLocation W30209304551 @default.
• W3020930455 hasOpenAccess W3020930455 @default.
• W3020930455 hasPrimaryLocation W30209304551 @default.
• W3020930455 hasRelatedWork W1551416944 @default.
• W3020930455 hasRelatedWork W1725314107 @default.
• W3020930455 hasRelatedWork W1884231116 @default.
• W3020930455 hasRelatedWork W2168798245 @default.
• W3020930455 hasRelatedWork W2360912380 @default.
• W3020930455 hasRelatedWork W2409990396 @default.
• W3020930455 hasRelatedWork W2566665866 @default.
• W3020930455 hasRelatedWork W2964012617 @default.
• W3020930455 hasRelatedWork W3197418554 @default.
• W3020930455 hasRelatedWork W4225393574 @default.
• W3020930455 hasVolume "203" @default.
• W3020930455 isParatext "false" @default.
• W3020930455 isRetracted "false" @default.
• W3020930455 magId "3020930455" @default.
• W3020930455 workType "article" @default.